No Data
No Data
Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $32
Goldman Sachs Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $32
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Cuts Target Price to $30
Kiniksa Issues Updates on Abiprubart, KPL-387, Mavrilimumab
Kiniksa Pharmaceuticals International | 10-K: FY2024 Annual Report
Earnings Call Summary | Kiniksa Pharmaceuticals International(KNSA.US) Q4 2024 Earnings Conference